SCHEMBL7902174

SCHEMBL7902174

CC(C)(C)OC(=O)CC[C@@H](C(=O)OC(C)(C)C)N(C(N)=O)c1ccc(N(CCCl)CCCl)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.37
ALDH1A1 P00352 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
HIF1A Q16665 3/20 0.37
LMNA P02545 3/20 0.37
ALOX15 P16050 2/20 0.37
NFKB1 P19838 2/20 0.37
THPO P40225 2/20 0.37
MAPT P10636 2/20 0.37
PMP22 Q01453 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
ABCB11 O95342 1/20 0.37
CHRM2 P08172 1/20 0.37
ADRA2A P08913 1/20 0.37
CHRM1 P11229 1/20 0.37
ACHE P22303 1/20 0.37
PTGS1 P23219 1/20 0.37
OPRM1 P35372 1/20 0.37
DRD3 P35462 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7902616 0.87
SCHEMBL7894832 0.78 S100B (0.35)
SCHEMBL7903786 0.78 ALDH1A1 (0.33) ALDH1A1
SCHEMBL9751830 0.77 EGFR (0.45) LMNAEGFRERBB2HDAC6
SCHEMBL7902158 0.77 ALDH1A1 (0.40) CYP3A4ALDH1A1SMN1; SMN2HIF1ALMNA
SCHEMBL7903865 0.74 MAPT (0.40) ALDH1A1SMN1; SMN2LMNAMAPTMEN1
SCHEMBL7906473 0.74 KMT2A (0.52) CYP3A4ALDH1A1SMN1; SMN2HIF1ALMNA
SCHEMBL8726196 0.72 CYP3A4 (0.46) CYP3A4ALDH1A1SMN1; SMN2HIF1ALMNA
SCHEMBL5571448 0.71 LTA4H (0.31)
SCHEMBL23394728 0.71 CYP3A4 (0.65) CYP3A4ALDH1A1SMN1; SMN2HIF1ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6277880-B1 ANTIBODY DIRECTED ENZYME PRODUG THERAPY ZENECA LIMITED (GB) 2001-08-21 US disclosed
EP-0651740-B1 AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS ZENECA LTD (GB) 1998-10-21 EP disclosed
US-5660829-A DEESTERIFYING COMPOUND TO FORM N-(4(N,N-BIS(2-CHLOROETHYL) AMINO)PHENOXYCARBONYL)-L-GLUTAMIC ACID-GAMMA-(3,5-DICARBOXY)ANILIDE ZENECA LIMITED (GB) 1997-08-26 US disclosed
US-5587161-A TWO COMPONENT SYSTEM INCLUDING ANTIBODY OR ANTIGEN BINDING FRAGMENT CONJUGATED TO CARBOXYPEPTIDASE G ENZYME, COMPOUND CONVERTIBLE TO CYTOTOXIC DRUG UNDER INFLUENCE OF ENZYME ZENECA LIMITED (GB) 1996-12-24 US disclosed
EP-0651740-A1 AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS ZENECA LIMITED (GB) 1995-05-10 EP disclosed
US-5405990-A For use in antibody directed enzyme prodrug therapy; cytotoxic parent nitrogen mustard; antitumor agents ZENECA LIMITED (GB) 1995-04-11 US disclosed
WO-1994002450-A1 AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS ZENECA LIMITED (GB) 1994-02-03 WO disclosed